Pierre Duquette

17.7k citations

129 papers · 7.2k indexed · 3 hit papers · h-index 42

Pathology and Forensic Medicine top 0.1%
- Multiple Sclerosis Research Studies 83
Immunology top 1%
- Immunotherapy and Immune Responses 11
- T-cell and B-cell Immunology 11
Neurology top 1%
- Neuroinflammation and Neurodegeneration Mechanisms 14
- Peripheral Neuropathies and Disorders 8
Neurology top 0.5%
- Neuroinflammation and Neurodegeneration Mechanisms 14
- Peripheral Neuropathies and Disorders 8
Rheumatology top 0.5%
- Systemic Lupus Erythematosus Research 10
Oncology
- Polyomavirus and related diseases 14
Hematology
- Autoimmune and Inflammatory Disorders Research 7

Co-authors: Marc Girard Alexandre Prat Jack P. Antel A. Dessa Sadovnick George C. Ebers Josée Poirier Nathalie Arbour Hania Kébir
Cited by: Pathology and Forensic Medicine Immunology Neurology
Partner nations: Canada United States United Kingdom

In The Last Decade

Pierre Duquette

122 papers receiving 6.9k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

1999 A Gender Gap in Autoimmunity
1993 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
1986 A Population-Based Study of Multiple Sclerosis in Twins

Peers

Countries citing papers authored by Pierre Duquette

Since Specialization

Citations

This map shows the geographic impact of Pierre Duquette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Duquette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Duquette more than expected).

Fields of papers citing papers by Pierre Duquette

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Duquette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Duquette. The network helps show where Pierre Duquette may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Pierre Duquette, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Pierre Duquette Line = papers co-authored together Pierre Duquette links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry Alessio Signori,Marta Ponzano,Tomáš Kalinčík,Serkan Özakbaş,Dana Horáková,Eva Havrdová,Raed Alroughani,Francesco Patti,Jens Kühle,Guillermo Izquierdo,Sara Eichau,Bassem Yamout,Samia J. Khoury,Rana Karabudak,Pierre Grammond,Pierre Duquette,Izanne Roos,Helmut Butzkueven,Anneke van der Walt,Maria Pia Sormani	2024	2
2	Cognitive and affective theory of mind in young and elderly patients with multiple sclerosis Maxime Montembeault,Romane Farley,Julie Ouellet,Estefania Brando,Alexandra Tremblay,Kim Charest,Élaine Roger,Peter Scherzer,Pierre Duquette,Isabelle Rouleau	2024	0
3	Long term effects of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea syndrome in multiple sclerosis patients Mylène Mazerolle,R. John Kimoff,Sulaiman Khadadah,Pierre Duquette,Vincent Jobin,Yves Lapierre,Andrea Benedetti,Katarina Majetic,Ann Robinson,Élaine Roger,Amit Bar‐Or,Marta Kamińska,Gabriel Leonard,Daria A. Trojan	2023	2
4	Clinical insights on the spasticity-plus syndrome in multiple sclerosis Kanza Alami Marrouni,Pierre Duquette	2022	1
5	Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations Mark S. Freedman,Virginia Devonshire,Pierre Duquette,Paul S. Giacomini,Fabrizio Giuliani,Michael C. Levin,Xavier Montalbán,Sarah A. Morrow,Jiwon Oh,Dalia Rotstein,E. Ann Yeh	2020	72
6	Detecting Subtle Cognitive Impairment in Multiple Sclerosis with the Montreal Cognitive Assessment Kim Charest,Alexandra Tremblay,Roxane Langlois,Élaine Roger,Pierre Duquette,Isabelle Rouleau	2020	16
7	Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers Laure Michel,Camille Grasmuck,Marc Charabati,Marc‐André Lécuyer,Stéphanie Zandee,Tessa Dhaeze,Jorge I. Alvarez,Rui Li,Sandra Larouche,Lyne Bourbonnière,Robert Moumdjian,Alain Bouthillier,Boaz Lahav,Pierre Duquette,Amit Bar‐Or,Jennifer L. Gommerman,Evelyn Peelen,Alexandre Prat	2019	47
8	A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies Pierre Duquette,Michael Yeung,Soukaïna Mouallif,Hamid Reza Nakhai-Pour,Paola Haddad,Robyn Schecter	2019	19
9	Assessing the risk of multiple sclerosis disease-modifying therapies Xavier Ayrignac,Philippe‐Antoine Bilodeau,Alexandre Prat,Marc Girard,Pierre Labauge,Jacques Le Lorier,Catherine Larochelle,Pierre Duquette	2019	8
10	Genome-wide scan identifies association between an interferon regulatory factor-related variant and interferon-beta induced liver injury in multiple sclerosis patients Kaarina Kowalec,Galen E.B. Wright,Britt I. Drögemöller,Folefac Aminkeng,Amit P. Bhavsar,Elaine Kingwell,Eric M. Yoshida,Anthony Traboulsee,Ruth Ann Marrie,Marcelo Kremenchutzky,T. Campbell,Pierre Duquette,N.P. Chalasani,Mia Wadelius,Pär Hallberg,Zongqi Xia,Philip L. De Jager,Colin J.D. Ross,Helen Tremlett,Bruce Carleton	2016	1
11	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study Ilya Kister,Tim Spelman,Raed Alroughani,Jeannette Lechner‐Scott,Pierre Duquette,François Grand’Maison,Mark Slee,Alessandra Lugaresi,Michael Barnett,Pierre Grammond,Gerardo Iuliano,Raymond Hupperts,Eugenio Pucci,María Trojano,Helmut Butzkueven	2016	64
12	The Impact of Treatment Adherence on Clinical and Economic Outcomes in Multiple Sclerosis: Real-World Evidence from Alberta, Canada Brittany Gerber,Thomas E. Cowling,G Chen,D Rivest,MM Yeung,Pierre Duquette,C Kindundu,M Barbeau,Peter Haddad	2016	5
13	Anti-JC Virus Antibody Prevalence in Canadian MS Patients Virender Bhan,Yves Lapierre,Mark S. Freedman,Pierre Duquette,Daniel Selchen,Vladimir Migounov,L. A. van der Walt,Annie Zhang	2014	16
14	Historical changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: a multicenter study Gerardo Iuliano,Cavit Boz,Edgardo Cristiano,Pierre Duquette,Alessandra Lugaresi,Celia Oreja‐Guevara,Vincent Van Pesch	2012	9
15	The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis Orla Gray,David Jolley,Jeannette Lechner‐Scott,Cees Zwanikken,María Trojano,François Grand’Maison,Pierre Duquette,Pierre Grammond,Roberto Bergamaschi,Giorgio Giuliani,Ruja Taffi	2009	3
16	Persistence of Immune Responses to Altered and Native Myelin Antigens in Patients with Multiple Sclerosis Treated with Altered Peptide Ligand H.J. Kim,Jack P. Antel,Pierre Duquette,David G. Alleva,Paul Conlon,Amit Bar‐Or	2002	40
17	Migration of Multiple Sclerosis Lymphocytes Through Brain Endothelium Alexandre Prat,Katarzyna Biernacki,Jean-François Lavoie,Josée Poirier,Pierre Duquette,Jack P. Antel	2002	100
18	The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis John H. Noseworthy,Peter C. O’Brien,Brandon J. Erickson,D. Lee,D. Sneve,George C. Ebers,G Rice,Anthony Auty,Walter Hader,Alan Kirk,Pierre Duquette,Jackson P. Carter,G. Francis,L Metz,Elizabeth A. Shuster	1998	74
19	A population‐based study of multiple sclerosis in twins: Update A. Dessa Sadovnick,Holly Armstrong,George P. Rice,Dennis E. Bulman,L. Hashimoto,D. W. Party,S. A. Hashimoto,Sharon Warren,Walter Hader,T. J. Murrary,Torrey Seland,Luanne M. Metz,Robert B. Bell,Pierre Duquette,T A Gray,Robert Nelson,B. Weinshenkar,David Brunt,George C. Ebers	1993	316
20	Multiple sclerosis in childhood: Clinical profile in 125 patients Pierre Duquette,Thomas J. Murray,J Pleines,George C. Ebers,A. Dessa Sadovnick,Patrick Weldon,Sharon Warren,D. W. Paty,A. C. Upton,Walter Hader,Robert Nelson,Anthony Auty,B.D. Neufeld,Carolyn C. Meltzer	1987	257

About Pierre Duquette

Pierre Duquette is a scholar working on Pathology and Forensic Medicine, Neurology and Immunology, having authored 129 papers that have together received 7.2k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (83 papers), Polyomavirus and related diseases (14 papers), Neuroinflammation and Neurodegeneration Mechanisms (14 papers), Immunotherapy and Immune Responses (11 papers), T-cell and B-cell Immunology (11 papers), Systemic Lupus Erythematosus Research (10 papers), Peripheral Neuropathies and Disorders (8 papers) and Autoimmune and Inflammatory Disorders Research (7 papers). The work is most often cited by research in Pathology and Forensic Medicine (4.1k citations), Immunology (2.4k citations) and Neurology (764 citations). Pierre Duquette has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Marc Girard, Alexandre Prat, Jack P. Antel, A. Dessa Sadovnick, George C. Ebers, Josée Poirier, Nathalie Arbour, Hania Kébir, Pierre J. Talbot and Igal Ifergan.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact